Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Stuttgart
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Biotec Pharmacon ASA

+ Add to Watchlist

B4V:GR

1.654 EUR 0.121 6.82%

As of 15:17:40 ET on 01/30/2015.

Snapshot for Biotec Pharmacon ASA (B4V)

Open: 1.719 Day's Range: 1.654 - 1.775 Volume: 2,000
Previous Close: 1.775 52wk Range: 1.250 - 2.750 1-Yr Rtn: +20.82%

Stock Chart for B4V

No chart data available.
  • B4V:GR 1.775
  • 1D
  • 1M
  • 1Y
1.775
Interactive B4V Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for B4V

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (NOK) (ttm) -
Est. EPS (NOK) (12/2014) -0.4300
Est. PEG Ratio -
Market Cap (M EUR) 72.15
Shares Outstanding (M) 43.62
30 Day Average Volume 699
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/17/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for B4V

  • Revenue
  • Net Income (M/NOK)
  • Profit Margin (%)

Company Profile & Key Executives for B4V

Biotec Pharmacon ASA develops, manufactures and markets immune modulating compounds for the human and animal health sectors and marine enzymes used in molecular biology. The Company develops products to prevent or treat diseases caused by the failure, imbalance, and over-reaction of the immune system.

Svein W F LienChief Executive OfficerArvid VangenCFO/CAO
Rolf EngstadCSO
More Company Profile & Key Executives for B4V

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil